Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• B-cell chronic lymphocytic leukemia (CLL) often presents with autoimmune complications, primarily affecting blood cells.
• Autoimmune hemolytic anemia (AIHA) is the most frequent autoimmune manifestation in CLL patients.
• CLL is considered a leading cause of AIHA, though the autoantibody source remains unclear.

Purpose of the Study:

• To review the clinical course and management of AIHA in the context of CLL.
• To explore the potential role of leukemic B-cells as antigen-presenting cells (APCs) in AIHA pathogenesis.
• To summarize current and emerging treatment strategies for CLL-associated AIHA.

Main Methods:

• Review of clinical literature and case series concerning CLL-associated AIHA.
• Discussion of pathogenetic hypotheses, including the role of leukemic B-cells as APCs.
• Analysis of treatment outcomes for various therapeutic interventions.

Main Results:

• Corticosteroids remain the primary treatment for CLL-associated AIHA.
• Steroid-refractory cases often require alternative therapies such as intravenous immunoglobulin, immunosuppressants, or splenectomy.
• Emerging evidence suggests the efficacy of anti-CD20 monoclonal antibodies, like rituximab, in managing this complication.

Conclusions:

• AIHA is a significant complication of CLL requiring careful management.
• The precise origin of autoantibodies in CLL-associated AIHA is still under investigation.
• Rituximab offers a promising therapeutic option for refractory cases of CLL-associated AIHA.